GNBT Rated BUY After Setting Dividend Record Date Of Nov 5 and Announcing Partnership With Canopy Growth Backed HydRx Farms
November 02 2018 - 9:41AM
InvestorsHub NewsWire
New York, NY -- November 2, 2018 --
InvestorsHub NewsWire -- Generex Biotechnology Corp (OTCQB:
GNBT) stock has been rated a BUY based on candle stick analysis.
The rating comes after the company announced a 20:1 for one dividend record date of
Monday, November 5th, 2018 with a rapid payment date the
next week on November 13th. Generex became a
prominent new player in the cannabis pharmaceutical sector recently
when the company announced a deal with HydRx Farms
Ltd. which is more commonly known by its operating name, Scientus
Pharma. Scientus is backed by Canopy Growth (NYSE: CGC).
The BUY rating was issued before the Generex BREAKING NEWS just published this morning on
the company’s acquisition of the remaining assets Vento
Holding.
“Our system’s recommendation today is
to BUY. The BULLISH ONE WHITE SOLDIER pattern finally
received a confirmation because the prices crossed above the
confirmation level which was at 9.9500, and our valid average
buying price stands now at
10.0150.
The green light is on and this security is
now screaming BUY. It is action time! The bullish pattern that
was previously identified is finally confirmed and a BUYsignal
is generated. Most probably, it is the right time to participate in
bullish fervor. Do not miss this bullish
opportunity”
AmericanBulls.com
See our previous release on Generex from
earlier this week:
Generex Enters $50 Billion Cannabis Pharmaceuticals
Sector With Canopy Growth Backed
Partner
Learn more about Generex at http://www.generex.com/
DISCLAIMER: NextBigTicker.com (NBT)is
a third party publisher and news dissemination service
provider. NBT is NOT affiliated in any manner with any company
mentioned herein. NBT is news dissemination solutions provider and
are NOT a registered broker/dealer/analyst/adviser, holds no
investment licenses and may NOT sell, offer to sell or offer to buy
any security. NBT's market updates, news alerts and corporate
profiles are NOT a solicitation or recommendation to buy, sell or
hold securities. The material in this release is intended to be
strictly informational and is NEVER to be construed or interpreted
as research material. All readers are strongly urged to perform
research and due diligence on their own and consult a licensed
financial professional before considering any level of investing in
stocks. All material included herein is republished content
and details which were previously disseminated by the companies
mentioned in this release or opinion of the writer. NBT is not
liable for any investment decisions by its readers or subscribers.
Investors are cautioned that they may lose all or a portion of
their investment when investing in stocks. NBT has not been
compensated for this release and HOLDS NO SHARES OF ANY
COMPANY NAMED IN THIS RELEASE.
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not
occur.
Source: www.nextbigticker.com
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From May 2024 to Jun 2024
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Jun 2023 to Jun 2024